[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
Ethics::
peer-review::
Indexing::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Journal DOI

AWT IMAGE

..
Copyright Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 
This Journal is licensed under a Creative Commons Attribution-NonCommercial 4.0
..
:: Volume 18, Issue 4 (4-2016) ::
J Babol Univ Med Sci. 2016; Volume 18 Back to browse issues page
Prevention of Hepatitis B Virus Reactivation in Kidney Transplant Recipients
H Nasri , SS Beladi Mousavi * , H Shahbazian , Sh Shayanpour , M Rafieian-Koupaei
, Beladimusavi@yahoo.com
Abstract:   (7856 Views)

BACKGROUND AND OBJECTIVE: Hepatitis B virus (HBV) reactivation is a major risk factor for hepatic dysfunction, acute or chronic hepatitis, cirrhosis, or hepatocellular carcinoma after kidney transplantation (KTP). The present article summarizes some of published articles about prevention of HBV reactivation in renal transplant recipients

METHODS: Many articles published in English language as full-text manuscripts reviewed in a variety of sources such as Scopus, Pub Med and Google Scholar with key words of hepatitis B and kidney transplantation to collect current data about this issue.

FINDINGS: The risk of reactivation of HBV followingKTP is related to the status of serologic markers of HBV at the time of KTP.KTP candidate patients who are hepatitis B surface antigen (HBsAg) positivehave higher risk for reactivation especially those who are hepatitis B e antibody positive or have high levels of HBV DNA in serum. Lamivudine has been most extensively used for prevention of HBV reactivation, but it is associated with a high rate of drug resistance.It seems that the optimal antiviral agent for prevention of HBV reactivation is entecavir which is associated with the lowest risk of drug resistance,however lamivudine-resistant HBV is less sensitive to entecavir. The preferred antiviral agent for lamivudine-resistant HBV is tenofovir which should be added to lamivudine rather than stopping lamivudine. It is reported that combination therapy in this sitting may reduce the development of resistance to the second drug.

CONCLUSION: There is sufficient evidence to recommend routine antiviral prophylaxis for all HBsAg-positive patients who are undergoing kidney transplantation.

Keywords: Hepatitis B, Kidney Transplantation, Entecavir, Tenofovir
Full-Text [PDF 252 kb]   (2710 Downloads)    
Type of Study: Review | Subject: Urology
Received: 2015/06/1 | Accepted: 2016/02/2 | Published: 2016/03/14
Send email to the article author



XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Nasri H, Beladi Mousavi S, Shahbazian H, Shayanpour S, Rafieian-Koupaei M. Prevention of Hepatitis B Virus Reactivation in Kidney Transplant Recipients. J Babol Univ Med Sci 2016; 18 (4) :48-55
URL: http://jbums.org/article-1-5503-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 18, Issue 4 (4-2016) Back to browse issues page
مجله علمی دانشگاه علوم پزشکی بابل Journal of Babol University of Medical Sciences

The Journal of Babol University of Medical Sciences is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Persian site map - English site map - Created in 0.05 seconds with 42 queries by YEKTAWEB 4645